General Information of Drug (ID: DMZK70E)

Drug Name
BN 50730 Drug Info
Synonyms
Rocepafant; BN 50730; UNII-4KGX1STY2N; BN-50730; 4KGX1STY2N; 132579-32-9; BN50730; 132418-36-1; 6-(2-Chlorophenyl)-9-((4-methoxyphenyl)thiocarbamoyl)-1-methyl-7,8,9,10-tetrahydro-4H-pyrido(4',3'-4,5)thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine; 4H-Pyrido(4',3'-4,5)thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine-9(8H)-carbothioamide, 6-(2-chlorophenyl)-7,10-dihydro-N-(4-methoxyphenyl)-1-methyl-; Rocepafant [INN]; LAU8080; LAU-8080; LAU 8080; AC1MHWNG; C27H25ClN6OS; SCHEMBL1065775; CHEMBL2105298; ZINC1481916; LS-172840
Indication
Disease Entry ICD 11 Status REF
Asthma CA23 Discontinued in Phase 3 [1]
Cross-matching ID
PubChem CID
3033963
CAS Number
CAS 132579-32-9
TTD Drug ID
DMZK70E

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ticlopidine DMO946V Acute coronary syndrome BA41 Approved [3]
RUPATADINE DMBPN7T N. A. N. A. Phase 4 [4]
ISRAPAFANT DMP61YB Asthma CA23 Phase 3 [5]
CMI-392 DM1NCUY Psoriasis vulgaris EA90 Phase 2 [6]
Lexipafant DMZ2YBE Nerve injury ND56.4 Phase 2 [7]
YM-264 DMAZNVX Sepsis 1G40-1G41 Phase 2 [8]
Dersalazine DMH96JW Inflammatory bowel disease DD72 Phase 2 [9]
60P002 DMHBN8X Dengue 1D20-1D2Z Phase 2 [10]
PegCNTF DMW7VGZ Obesity 5B81 Phase 1 [11]
FOROPAFANT DML1DGP Asthma CA23 Discontinued in Phase 3 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Platelet-activating factor receptor (PTAFR) TTQL5VC PTAFR_HUMAN Modulator [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001346)
2 Platelet-activating factor antagonist BN 50730 attenuates hypoxic-ischemic brain injury in neonatal rats. Pediatr Res. 2001 Jun;49(6):804-11.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4 Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43.
5 Amino acid residues critical for endoplasmic reticulum export and trafficking of platelet-activating factor receptor. J Biol Chem. 2010 Feb 19;285(8):5931-40.
6 Anti-inflammatory activities of LDP-392, a dual PAF receptor antagonist and 5-lipoxygenase inhibitor. Pharmacol Res. 2001 Sep;44(3):213-20.
7 Lexipafant and acute pancreatitis: a critical appraisal of the clinical trials.Eur J Surg.2002;168(4):215-9.
8 Effects of YM264, a novel PAF antagonist, on puromycin aminonucleoside-induced nephropathy in the rat. Biochem Biophys Res Commun. 1991 Apr 30;176(2):781-5.
9 The intestinal anti-inflammatory effect of dersalazine sodium is related to a down-regulation in IL-17 production in experimental models of rodent colitis. Br J Pharmacol. 2012 February; 165(3): 729-740.
10 Clinical pipeline report, company report or official report of 60 Degrees Pharmaceuticals.
11 Sch 37370: a new drug combining antagonism of platelet-activating factor (PAF) with antagonism of histamine. Agents Actions Suppl. 1991;34:313-21.
12 Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist. J Pharmacol Exp Ther. 1991 Oct;259(1):44-51.